Latest news with #Heartflow
Business Upturn
23-07-2025
- Business
- Business Upturn
Heartflow Plaque Analysis to be Covered by UnitedHealthcare Plans Nationwide
MOUNTAIN VIEW, Calif., July 22, 2025 (GLOBE NEWSWIRE) — Heartflow, Inc. , the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis will be covered by UnitedHealthcare across all lines of business, including Commercial, Medicare Advantage, and Community plans. UnitedHealthcare is the first insurer to update its policies to cover Heartflow Plaque Analysis to fully align with the guidelines recently issued by radiology benefit manager EviCore. 'UnitedHealthcare's decision to cover Heartflow Plaque Analysis nationwide is a tremendous step in advancing patient access to our proven AI-driven plaque technology,' said John Farquhar, President and CEO of Heartflow. 'We are pleased that this major commercial payer recognizes the innovation and value that Heartflow's technology can provide to its members and healthcare providers in diagnosing and managing coronary artery disease. This decision will increase access for early detection and quantification of plaque using our precision Plaque Analysis tool, setting a new standard for cardiovascular care coverage.' The updated coverage will become effective October 1, 2025 for patients with acute or stable chest pain and mild-to-moderate narrowing of coronary arteries (1-70% stenosis) found on coronary computed tomography angiography (CCTA). Expanded access will allow for greater adoption of Heartflow Plaque Analysis for clinicians to incorporate into their diagnostic and patient management protocols, delivering more personalized treatment. Heartflow Plaque Analysis is the only FDA-cleared, AI-enabled, noninvasive plaque quantification tool with a reported 95% agreement with the gold standard, IVUS, in a prospective, global trial using blinded core lab adjudication.1 It is proven to change medical management in over half of patients beyond CCTA alone, helping physicians to improve outcomes.2 This coverage milestone follows the recent presentation of clinical outcomes from the DECIDE registry, which found management changes informed by Heartflow Plaque Analysis led to an average LDL cholesterol decrease of 18.7mg/dL.3 This clinically significant reduction is associated with an estimated 15% decrease in the risk of a cardiac event, highlighting the potential of Heartflow Plaque Analysis to improve patient outcomes by guiding more effective medical therapy and interventions.4 Heartflow is dedicated to transforming CAD from the leading cause of death to a disease that can be proactively managed for life. In the United States, CAD is estimated to be responsible for one heart attack every 40 seconds and one out of every five deaths.5 Heartflow has been adopted by more than 1,400 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population worldwide. About Heartflow, Inc. Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosable, and manageable condition. Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway. The AI-driven platform — including Roadmap™ Analysis , FFR CT Analysis and Plaque Analysis — is supported by the ACC/AHA Chest Pain Guideline and backed by more than 600 peer-reviewed publications. Heartflow has helped clinicians manage over 400,000 patients worldwide. Discover how we're shaping the future of cardiovascular care at . Media Contact Elliot Levy [email protected]
Time of India
18-07-2025
- Business
- Time of India
Healthcare firm Heartflow's IPO filing discloses wider loss
Bengaluru: Heartflow's quarterly loss widened over the year-ago period, the healthcare company disclosed in its paperwork for a U.S. initial public offering on Thursday, at a time when it looks to tap into renewed investor appetite for new listings. The U.S. IPO market is recovering from months of sluggish activity triggered by trade policy uncertainty under President Donald Trump. Both Omada, a virtual healthcare provider, and cancer diagnostic firm Caris Life Sciences saw strong investor reception when they debuted last month. Mountain View, California-based Heartflow posted a loss of $32.3 million for the three months ended March 31, compared with a loss of $20.9 million a year earlier, the IPO filing showed. Its revenue was $37.2 million for the quarter, compared with $26.8 million a year ago. Proceeds from the IPO will be used to pay down debt, fund sales and marketing, research and product development activities and other general corporate purposes, the company said. Heartflow develops an artificial intelligence-powered heart imaging tool, which creates personalized 3D models of the organ, helping doctors detect blockages, minimize unnecessary testing and optimize treatment. The company will list on the Nasdaq under the symbol "HTFL".
Reuters
17-07-2025
- Business
- Reuters
Healthcare firm Heartflow's IPO filing discloses wider loss
July 17 (Reuters) - Heartflow's quarterly loss widened over the year-ago period, the healthcare company disclosed in its paperwork for a U.S. initial public offering on Thursday, at a time when it looks to tap into renewed investor appetite for new listings. The U.S. IPO market is recovering from months of sluggish activity triggered by trade policy uncertainty under President Donald Trump. Both Omada (OMDA.O), opens new tab, a virtual healthcare provider, and cancer diagnostic firm Caris Life Sciences (CAI.O), opens new tab saw strong investor reception when they debuted last month. Mountain View, California-based Heartflow posted a loss of $32.3 million for the three months ended March 31, compared with a loss of $20.9 million a year earlier, the IPO filing showed. Its revenue was $37.2 million for the quarter, compared with $26.8 million a year ago. Proceeds from the IPO will be used to pay down debt, fund sales and marketing, research and product development activities and other general corporate purposes, the company said. Heartflow develops an artificial intelligence-powered heart imaging tool, which creates personalized 3D models of the organ, helping doctors detect blockages, minimize unnecessary testing and optimize treatment. The company will list on the Nasdaq under the symbol "HTFL". J.P. Morgan, Morgan Stanley and Piper Sandler are among the underwriters for the offering.
Yahoo
17-07-2025
- Business
- Yahoo
Medical device software developer Heartflow files for US IPO
(Reuters) -Heartflow, an artificial intelligence-based medical device software developer, filed for an initial public offering in the United States on Thursday. The U.S. IPO market is witnessing a renewed vigor as investors return following months of sluggish activity triggered by trade policy uncertainty under President Donald Trump, earlier this year. Heartflow will list on the Nasdaq under the symbol "HTFL". J.P. Morgan, Morgan Stanley and Piper Sandler are among the underwriters for the offering. Sign in to access your portfolio
Reuters
17-07-2025
- Business
- Reuters
Medical device software developer Heartflow files for US IPO
July 17 (Reuters) - Heartflow, an artificial intelligence-based medical device software developer, filed for an initial public offering in the United States on Thursday. The U.S. IPO market is witnessing a renewed vigor as investors return following months of sluggish activity triggered by trade policy uncertainty under President Donald Trump, earlier this year. Heartflow will list on the Nasdaq under the symbol "HTFL". J.P. Morgan, Morgan Stanley and Piper Sandler are among the underwriters for the offering.
